Electromed (ELMD) Q3 2025 earnings summary

Executive summary

• Achieved tenth consecutive quarter of year-over-year revenue and net income growth, with Q3 FY 2025 revenue up 13.1% to $15.7 million and net income up 26.7% to $1.9 million, or $0.21 per diluted share, driven by strong operational execution and market development initiatives.

• Net revenues for the nine months ended March 31, 2025, increased 16.9% year-over-year to $46.6 million, with net income rising to $5.3 million, reflecting higher gross profit and operating leverage.

• Focused on airway clearance for bronchiectasis, expanding direct sales team to 55 reps, launching targeted marketing initiatives, and a Veterans Administration direct-to-consumer outreach program in 11 cities.

• Enhanced operational efficiency with a new ePrescribe solution, refreshed product page, and ergonomic upgrades to SmartVest luggage.

• Gross margin improved to 78.0% for both the quarter and nine-month period, up from 74.8% and 76.3% in the prior year.

Financial highlights

• Net revenues grew 13.1% year-over-year to $15.7 million in Q3; direct home care revenue rose 14.8% to $14.1 million.

• Homecare revenue for the nine months grew 16.1% to $41.9 million; hospital revenue up 11.9% to $2.1 million.

• Gross profit increased to $12.2 million (78.0% of net revenues), up from $10.4 million (74.8%).

• Operating income was $2.1 million (13.6% margin) in Q3 and $6.6 million for the nine months, up 55.9% year-over-year.

• Quarterly EPS reached $0.21 per diluted share; nine-month EPS (diluted) was $0.59, up from $0.38 in the prior year.

• Cash balance at $15.2 million as of March 31, 2025, with no debt and working capital of $35.7 million.

• Net cash provided by operating activities was $7.5 million for the nine months, up from $4.6 million in the prior year.

• Cash decreased by $0.8 million over nine months, mainly due to $6.3 million in share repurchases and $2.3 million in taxes, offset by $7.5 million in positive operating cash flow.

Outlook and guidance

• Plans to continue deliberate expansion of sales force, including additional hires for hospital business and ongoing investments in infrastructure and product enhancements.

• Targeting revenue per sales rep of $1 million or higher, with potential to revise upward in the next fiscal year.

• New CRM system to launch in early Q1 FY 2026, expected to integrate disparate systems and enhance productivity.

• Management expects current working capital and available credit to provide sufficient liquidity for at least the next twelve months.

• Cash flows from operations and available credit are expected to cover capital expenditures and operational needs for fiscal 2025 and the foreseeable future.